{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:07:44Z","timestamp":1777417664258,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2002,4]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To evaluate current scientific literature regarding the efficacy of risedronate in the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>Primary research articles were identified by MEDLINE search (1966\u2013May 2001) and through secondary sources. Key search terms were risedronate, postmenopausal osteoporosis, and fractures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:<\/jats:title>\n                    <jats:p>Osteoporosis results in a reduction of bone mineral density, increased bone fragility, and increased risk of fractures. The goal of osteoporosis therapy is not only to increase bone mass, but also to reduce the rate of fractures. Risedronate is the newest bisphosphonate to be approved for the prevention and treatment of osteoporosis. An evaluation of clinical trials using risedronate in the treatment of postmenopausal osteoporosis was performed to determine its efficacy at decreasing fracture rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Risedronate is an effective and safe option for the treatment of postmenopausal osteoporosis. Risedronate significantly decreases the risk of vertebral and nonvertebral fractures in women who have had \u22651 fractures in the past. More studies are warranted to evaluate the efficacy of risedronate in women without preexisting vertebral fractures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1a221","type":"journal-article","created":{"date-parts":[[2003,6,4]],"date-time":"2003-06-04T16:20:40Z","timestamp":1054743640000},"page":"664-670","source":"Crossref","is-referenced-by-count":4,"title":["Risedronate for the Prevention of Fractures in Postmenopausal Osteoporosis"],"prefix":"10.1177","volume":"36","author":[{"given":"Jennifer M","family":"Sickels","sequence":"first","affiliation":[{"name":"Jennifer M Sickels PharmD BCPS, Assistant Clinical Specialist, School of Pharmacy, Northeastern University, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Sing","family":"Nip","sequence":"additional","affiliation":[{"name":"Chi-Sing Nip PharmD, Post-Doctoral Fellow, Hoffmann-La Roche, Nutley, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2002,4,1]]},"reference":[{"key":"bibr-bibr1-aph.1A221","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.6.785"},{"key":"bibr-bibr2-aph.1A221","first-page":"2","volume":"93","author":"Igbal MM","year":"2000","journal-title":"South Med J"},{"key":"bibr-bibr3-aph.1A221","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803123381107"},{"key":"bibr-bibr4-aph.1A221","doi-asserted-by":"publisher","DOI":"10.1007\/PL00022721"},{"key":"bibr-bibr5-aph.1A221","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(95)00258-4"},{"key":"bibr-bibr6-aph.1A221","unstructured":"Drug prices and information [cited 2002 Mar 12]. Available from: URL: http:\/\/www.drugstore.com\/pharmacy\/drugindex."},{"key":"bibr-bibr7-aph.1A221","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.22.2891"},{"key":"bibr-bibr8-aph.1A221","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03899.x"},{"key":"bibr-bibr9-aph.1A221","unstructured":"Package insert. Fosamax (alendronate). Whitehouse Station, NJ: Merck & Co., November 1999."},{"key":"bibr-bibr10-aph.1A221","unstructured":"Package insert. Actonel (risedronate). Cincinnati, OH: Procter & Gamble Pharmaceuticals, April 2000."},{"key":"bibr-bibr11-aph.1A221","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511303332201"},{"key":"bibr-bibr12-aph.1A221","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07088-2"},{"key":"bibr-bibr13-aph.1A221","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.24.2077"},{"key":"bibr-bibr14-aph.1A221","doi-asserted-by":"publisher","DOI":"10.1007\/PL00004152"},{"key":"bibr-bibr15-aph.1A221","first-page":"396","volume":"83","author":"Mortensen L","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"bibr-bibr16-aph.1A221","first-page":"1895","volume":"85","author":"Fogelman I","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"bibr-bibr17-aph.1A221","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.14.1344"},{"key":"bibr-bibr18-aph.1A221","doi-asserted-by":"publisher","DOI":"10.1007\/s001980050010"},{"key":"bibr-bibr19-aph.1A221","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102013440503"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1A221","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1A221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:05:27Z","timestamp":1777374327000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1A221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["10.1345\/aph.1A221"],"URL":"https:\/\/doi.org\/10.1345\/aph.1a221","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}